Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Nov 17, 2023 (filed on Nov 21, 2023)Insider Name:Demopulos Gregory A MDOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:15,000Price:$1.68
-
Nov 15, 2023 (filed on Nov 17, 2023)Insider Name:Demopulos Peter A MDOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:10,000Price:$1.53
-
Nov 14, 2023 (filed on Nov 15, 2023)Insider Name:Demopulos Gregory A MDOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:25,000Price:$1.44
-
Nov 13, 2023 (filed on Nov 15, 2023)Insider Name:Demopulos Gregory A MDOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:37,500Price:$1.29
-
Sep 22, 2023 (filed on Sep 27, 2023)Insider Name:Demopulos Gregory A MDOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:715,000Price:--
-
Sep 22, 2023 (filed on Sep 27, 2023)Insider Name:Jacobsen Michael AOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:100,000Price:--
-
Sep 22, 2023 (filed on Sep 27, 2023)Insider Name:Cancelmo Peter BOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:100,000Price:--
-
Sep 12, 2023 (filed on Sep 14, 2023)Insider Name:Bumol Thomas F.Ownership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:10,000Price:$3.31
-
Jun 23, 2023 (filed on Jun 27, 2023)Insider Name:Hanish Arnold COwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:15,000Price:--
-
Jun 23, 2023 (filed on Jun 27, 2023)Insider Name:Hood Leroy E. MD PhDOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:15,000Price:--
Filings by filing date
-
Nov 17, 2023 (filed on Nov 21, 2023)Insider Name:Demopulos Gregory A MDOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:15,000Price:$1.68
-
Nov 15, 2023 (filed on Nov 17, 2023)Insider Name:Demopulos Peter A MDOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:10,000Price:$1.53
-
Nov 14, 2023 (filed on Nov 15, 2023)Insider Name:Demopulos Gregory A MDOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:25,000Price:$1.44
-
Nov 13, 2023 (filed on Nov 15, 2023)Insider Name:Demopulos Gregory A MDOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:37,500Price:$1.29
-
Sep 22, 2023 (filed on Sep 27, 2023)Insider Name:Demopulos Gregory A MDOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:715,000Price:--
-
Sep 22, 2023 (filed on Sep 27, 2023)Insider Name:Jacobsen Michael AOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:100,000Price:--
-
Sep 22, 2023 (filed on Sep 27, 2023)Insider Name:Cancelmo Peter BOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:100,000Price:--
-
Sep 12, 2023 (filed on Sep 14, 2023)Insider Name:Bumol Thomas F.Ownership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:10,000Price:$3.31
-
Jun 23, 2023 (filed on Jun 27, 2023)Insider Name:Hanish Arnold COwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:15,000Price:--
-
Jun 23, 2023 (filed on Jun 27, 2023)Insider Name:Hood Leroy E. MD PhDOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:15,000Price:--
News
Biz Brief
Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 201 Elliott Avenue West SEATTLE WA 98119 |
Tel: | N/A |
Website: | https://www.omeros.com |
IR: | See website |
Key People | ||
Gregory A. Demopulos Chairman of the Board, President, Chief Executive Officer | Tina Quinton Vice President - Patents | Michael A. Jacobsen Vice President - Finance, Chief Accounting Officer, Treasurer |
George A. Gaitanaris Vice President - Science, Chief Scientific Officer | Peter B. Cancelmo Vice President, General Counsel, Secretary | Peter W. Williams Vice President - Human Resources |
Debra K. Bowes Vice President, Chief Business Development Officer | Nadia Dac Vice President, Chief Commercial Officer | Mariana Dimitrova Vice President - Chemistry, Manufacturing and Controls | Catherine A. Melfi Vice President - Regulatory Affairs and Quality Systems, Chief Regulatory Officer |
Business Overview |
Omeros Corporation is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, COVID-19, and atypical hemolytic uremic syndrome. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria, complement 3 (C3) glomerulopathy and one or more related indications. |
Financial Overview |
For the nine months ended 30 September 2023, Omeros Corp revenues was not reported. Net loss before extraordinary items increased less than 1% to $135.6M. Net income also reflects Interest and other income increase from $2.1M to $12.9M (income), Stock-based compensation expense decrease of 12% to $5.5M (expense), Stock-based Compensation in R&D decrease of 7% to $4.5M (expense). |
Employees: | 196 as of Dec 31, 2022 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $348.74M as of Sep 30, 2023 |
Annual revenue (TTM): | $0.00M as of Sep 30, 2023 |
EBITDA (TTM): | -$164.03M as of Sep 30, 2023 |
Net annual income (TTM): | -$181.68M as of Sep 30, 2023 |
Free cash flow (TTM): | $84.12M as of Sep 30, 2023 |
Net Debt Last Fiscal Year: | $131.85M as of Sep 30, 2023 |
Shares outstanding: | 62,865,491 as of Nov 7, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |